Glucose and metabolic health markers is closer to a research marker, so it should be read separately from a directly felt benefit.
Representative tier calculated from paper evidence that passed the collection audit.
The representative ingredient tier is calculated from these target-level evidence groups.
10 new papers were added in this period. No new risk signal was identified.
Standalone side-effect signals and combination cautions are listed separately.
No standalone side-effect or combination signal is currently clear enough to show from the collected papers. This does not mean there is no concern.
Paper IDs and full lists are private. Only study types and summaries are shown.
Though LA has long been touted as an antioxidant, it has also been shown to improve glucose and ascorbate handling, increase eNOS activity, activate Phase II detoxification via the transcription factor Nrf2, and lower expression of MMP-9 and VCAM-1 through rep
The combination of ω-3 + LA slowed cognitive and functional decline in AD over 12 months and further evaluation of the combination of omega-3 fatty acids plus alpha-lipoic acid as a potential treatment is warranted.
Alpha-lipoic acid and spinal cord stimulation were effective for pain; studies were short-term with quality deficits and further research should address long-term outcomes and other non-pharmacologic treatments.
Four biopsy-proven cases of neural epidermal growth factor-like 1 (NELL1)-associated membranous nephropathy following lipoic acid supplementation and a fifth suspected case are described.
It is speculated that alpha-lipoic acid might have an antioxidant effect in pediatric diabetes patients by reducing insulin, unlike diet with placebo or controls.
LA supplementation decreased lipid peroxidation and oxidative damage of proteins and improved non-enzymatic antioxidant capacity in healthy controls and no significant changes were observed on oxidative damage in patients with schizophrenia.